PRODUCTION OF ANTIBODIES AGAINST HER2 AND HER3 RECEPTORS IN BREAST CANCER TREATMENT AND THE SUPERIOR EFFECT OF THE SYNCHRONOUS BLOCKADE OF THESE RECEPTORS

被引:0
|
作者
Hedayatizadeh-Omran, A. [1 ,2 ]
Rafiei, A. [2 ,3 ]
Janbabaei, G. [1 ]
Ajami, A. [3 ]
Valadan, R. [2 ]
Alizadeh-Navaei, R. [1 ,2 ]
Tehrani, M. [2 ,3 ]
Omrani-Nava, V. [1 ]
Ahmadi, A. [4 ]
机构
[1] Mazandaran Univ Med Sci, Fac Med, Gastrointestinal Canc Res Ctr, Sari, Iran
[2] Mazandaran Univ Med Sci, Mol & Cell Biol Res Ctr, Sari, Iran
[3] Mazandaran Univ Med Sci, Dept Immunol, Fac Med, Sari, Iran
[4] Mazandaran Univ Med Sci, Pharmaceut Sci Res Ctr, Fac Pharm, Sari, Iran
关键词
HER2; HER3; Antibody; Phage display;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: The human epidermal growth factor receptor family (ErbB receptor family) plays an important role in the development of cancer. Antibody phage display technique is one of the powerful techniques that allows highly specific selection for antibody selection. Materials and Methods: In this study, by using antibody phage display technique, which is one of the powerful techniques for making antibodies in vitro, recombinant antibodies against ErbB2 and ErbB3 receptors were produced for inhibition of these receptors and compared the simultaneous blockage of these receptors with a synchronous block of HER2 and HER3. Results: We established a panel of stable cell lines expressing high levels of HER2 and HER3 and then we have produced antibodies with phage display technique against ErbB2 and ErbB3 receptors and compared the simultaneous blockage of these receptors with a synchronous block of HER2 and HER3. Conclusions: The specificity of antibodies obtained in this method was greatly improved and we've shown that synchronous block of HER2 and HER3 receptors has a superior effect compared with the monospecific block.
引用
收藏
页数:9
相关论文
共 50 条
  • [1] Combinatorial blockade of ERBB receptors in HER2 low breast cancer
    Berdiel-Acer, Mireia
    Reinz, Eileen
    Abnaof, Khalid
    Burmester, Sara
    Will, Rainer
    Korf, Ulrike
    Wiemann, Stefan
    CANCER RESEARCH, 2017, 77
  • [2] RABBIT ANTIBODIES FOR HORMONE RECEPTORS AND HER2 EVALUATION IN BREAST CANCER
    Rocha, Rafael Malagoli
    Nunes, Cristiana Buzelin
    Fernandes Sanches, Fernanda Squarcio
    Silva Rocha, Gislene Fatima
    de Oliveira, Flavio Nepomuceno
    Reis-Filho, Jorge Sergio
    Lambros, Maryou B.
    Gobbi, Helenice
    REVISTA DA ASSOCIACAO MEDICA BRASILEIRA, 2009, 55 (02): : 163 - 168
  • [3] The upgraded role of HER3 and HER4 receptors in breast cancer
    Koutras, Angelos K.
    Fountzilas, George
    Kalogeras, Konstantine T.
    Starakis, Ioannis
    Iconomou, Gregoris
    Kalofonos, Haralabos P.
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2010, 74 (02) : 73 - 78
  • [4] Specific antibodies and sensitive immunoassays for the human epidermal growth factor receptors (HER2, HER3, and HER4)
    Broughton, Marianne Nordlund
    Westgaard, Arne
    Paus, Elisabeth
    Oijordsbakken, Miriam
    Henanger, Karoline J.
    Naume, Bjorn
    Bjoro, Trine
    TUMOR BIOLOGY, 2017, 39 (06) : 1 - 11
  • [5] Blockade of the HER Family of Receptors in the Treatment of HER2-Positive Metastatic Breast Cancer
    Sachdev, Jasgit C.
    Jahanzeb, Mohammad
    CLINICAL BREAST CANCER, 2012, 12 (01) : 19 - 29
  • [6] Cluster Analysis of Endogenous HER2 and HER3 Receptors in SKBR3 Cells
    Roberts, Selene K.
    Hirsch, Michael
    McStea, Alexandra
    Zanetti-Domingues, Laura C.
    Clarke, David T.
    Claus, Jeroen
    Parker, Peter J.
    Wang, Lin
    Martin-Fernandez, Marisa L.
    BIO-PROTOCOL, 2018, 8 (23):
  • [7] Co-occurring gain-of-function mutations in HER2 and HER3 modulate HER2/HER3 activation, breast cancer progression, and HER2 inhibitor sensitivity
    Hanker, Ariella B.
    Jayanthan, Harikrishna Sekar
    Ye, Dan
    Lin, Chang-Ching
    Akamatsu, Hiroaki
    Sheehan, Jonathan H.
    Koch, James P.
    Sudhan, Dhivya R.
    Brewer, Monica Red
    Servetto, Alberto
    He, Jie
    Miller, Vincent A.
    Lalani, Alshad S.
    Meiler, Jens
    Arteaga, Carlos L.
    CANCER RESEARCH, 2020, 80 (04)
  • [8] Four-in-One Antibodies Have Superior Cancer Inhibitory Activity against EGFR, HER2, HER3, and VEGF through Disruption of HER/MET Crosstalk
    Hu, Shi
    Fu, Wenyan
    Xu, Weihao
    Yang, Yang
    Cruz, Melissa
    Berezov, Sandra D.
    Jorissen, Daniel
    Takeda, Hiroaki
    Zhu, Wangdong
    CANCER RESEARCH, 2015, 75 (01) : 159 - 170
  • [9] Novel Peptidomimetics for Inhibition of HER2:HER3 Heterodimerization in HER2-Positive Breast Cancer
    Kanthala, Shanthi
    Banappagari, Sashikanth
    Gokhale, Ameya
    Liu, Yong-Yu
    Xin, Gu
    Zhao, Yunfeng
    Jois, Seetharama
    CHEMICAL BIOLOGY & DRUG DESIGN, 2015, 85 (06) : 702 - 714
  • [10] Role for HER2/neu and HER3 in fulvestrant-resistant breast cancer
    Osipo, Clodia
    Meeke, Kathleen
    Cheng, Dong
    Weichel, Alyssa
    Bertucci, Anne
    Liu, Hong
    Jordan, V. Craig
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2007, 30 (02) : 509 - 520